6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7(8H)-one is used to prepare pyridino[2,3-d]pyrimidin-7(8H)-one derivatives as CDK4 and/or CDK6 inhibitors useful in the treatment of diseases.
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one is a pharmaceutical intermediate that can be used to synthesize Palbociclib, an inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 for the treatment of breast cancer.
6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one is a White Solid. Slightly soluble in methanol, chloroform and DMSO.
6-bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one is a key intermediate in the synthesis of Ibrance[1]. The structural feature of this compound lies in its incorporation of two functional groups—bromine and chlorine—which heighten its reactivity during synthesis. Furthermore, it may also be employed in the synthesis of palbociclib and its salt derivatives[2].
[1] HANHAN XU. Solid–Liquid Equilibrium and Thermodynamic Properties of 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3]pyrimidin-7(8H)-one in 10 Pure Solvents and 3 Different Miscible Systems at T = (278.15–323.15) K[J]. Journal of Chemical & Engineering Data, 2021, 66 8: 3323-3334. DOI:10.1021/acs.jced.1c00362.
[2] KOCIEŇSKI P. Synthesis of Palbociclib[J]. Synfacts, 2016, 60 1: 1012-1012. DOI:10.1055/S-0036-1589195.